Search

BACKGROUND: Partial pressure of end-tidal carbon dioxide (...) monitoring in children is important to detect apnea or hypopnea early to intervene before hypoxemia develops. Monitoring ... in children without a tracheal tube is challenging. To improve ... measurement accuracy in a commercially available mask with a mainstream CO2 detector, we implemented design changes with deform-and-hold shaping technology and anterior-posterior adjustment of the expiratory gas flow cup. METHODS: Two sizes of redesigned face masks (small for 7-20 kg, medium for 10-40 kg) were evaluated. Initial bench testing used a simulator modeling a spontaneously breathing infant and child with a natural airway. An infant/child manikin head was connected to the breathing lung simulator. A mass flow controller provided expiratory CO2. Mask fit was then evaluated on healthy human subjects to identify anatomical features associated with good fit, defined as square shape capnography waveform during expiration. A 3-dimensional digital scan was used to quantify anatomical features. The gaps between face mask rims and facial surface were manually measured. RESULTS: Bench testing revealed a ... difference of 3.4 ± 1.5 mm Hg between a measured ... by the redesigned mask and CO2 concentration at trachea, as compared with 6.7 ± 6.2 mm Hg between ... measured by nasal cannula and trachea (P < .001). In the human mask fit study, 35 children (13 ± 4 kg) with the small mask and 38 (24 ± 8 kg) with the medium mask were evaluated. Capnography tracing was successfully obtained in 86% of the small and 100% of the medium masks. In children with small-size masks, the gap between the face mask rim and the child's face was not statistically different among those with good mask fit and without (1.0 ± 1.5 mm vs 1.4 ± 1.9 mm, P = .73). CONCLUSIONS: ... measurement by a redesigned open-system face mask with a mainstream CO2 detector was accurate in the bench setting. The redesigned face mask can attain good mask fit and accurate capnography tracings in the majority of infants and children. [ABSTRACT FROM AUTHOR]

Background: Mitral valve (MV) repair is performed with less frequency than MV replacement in older persons, with referral often delayed until symptoms are severe. Surgical practice in this population remains inconsistent in the absence of national MV repair outcomes. The goal of this study was to assess durability and longitudinal outcomes after isolated primary MV repair in patients aged 65 years or more. Methods: We linked clinical data from The Society of Thoracic Surgeons adult cardiac surgery database (STS) to longitudinal claims data from the Centers for Medicare and Medicaid Services (CMS). Between January 1991 and December 2007, we identified 14,604 isolated nonemergent primary MV repair operations in STS-CMS data. These were longitudinally examined for mortality, mitral reoperation, and readmissions for heart failure, bleeding, and stroke. Predictors of 5-year death after MV repair were identified using Cox proportional hazard modeling. Results: The study cohort had a mean age of 73.3 ± 5.5 years, ejection fraction 54.0% ± 12.9%; 55.8% (8,148 of 14,604) were female; and 8.4% (1,233 of 14,604) were non-Caucasian. Operative mortality was 2.59% (378 of 14,604). Mean follow-up was 5.9 ± 3.9 years (range, 1.0 to 18.0). Survival during follow-up was 74.9% (10,934 of 14,604). The number of observed events for mitral reoperation, heart failure, bleeding, and stroke were 552 of 14,604 (3.7%), 2,681 of 14,604 (18.4%), 1,051 of 14,604 (7.2%), and 1,131 of 14,604 (7.7%), respectively. The 10-year Kaplan-Meier event rates for mitral reoperation, heart failure, bleeding, and stroke were 6.2%, 30.1%, 15.3%, and 16.4%, respectively. The 10-year actuarial survival of 57.4% was equivalent to the matched US population. Conclusions: Utilizing linked STS and CMS databases, we demonstrate that MV repair is a safe and durable long-term option for older patients. Survival restored to the normal population suggests repair may suppress the longitudinal impact of mitral regurgitation in the elderly and that the practice of delayed referral should be reevaluated. These data provide a contemporary longitudinal benchmark of MV repair outcomes. [Copyright &y& Elsevier]

Clinical guidelines continue to move away from routine prostate specific antigen screening (PSA), once a widespread medical practice. A curious difference exists between early prostate cancer and early breast cancer. While randomized trials of therapy in early breast cancer continue to show overall survival benefit, this is not the case in prostate cancer, where prostatectomy was no better than observation in a recent trial, and where early androgen deprivation is no better than late androgen deprivation. Here, I make the case that prostate cancer screening contributes so greatly to over diagnosis that even treatment trials yield null results due to contamination with non-life threatening disease. [ABSTRACT FROM AUTHOR]

Low-value health care services that provide little or no benefit to patients are common, potentially harmful, and costly. Nearly half of the patients in the United States will receive at least 1 low-value test or procedure annually, creating risk of avoidable complications from subsequent cascades of care and excess costs to patients and society. Reducing low-value care is of particular importance to cardiovascular health given the high prevalence and costs of cardiovascular disease in the United States. This scientific statement describes the current scope and impact of low-value cardiovascular care; reviews existing literature on patient-, clinician-, health system-, payer-, and policy-level interventions to reduce low-value care; proposes solutions to achieve meaningful and equitable reductions in low-value care; and suggests areas for future research priorities. [ABSTRACT FROM AUTHOR]

Efficient durable viral vector transduction of the transplanted heart remains elusive. This study assesses the potential of recombinant adeno-associated virus (rAAV) mediated gene delivery to the transplanted rat heart. rAAV serotype 1, 2 and 5 vectors encoding the green fluorescent protein (GFP) gene (1 × 1011 viral particles/ml) were diluted in cold University of Wisconsin solution and circulated through the coronary vasculature of the donor organs for 30 min before syngeneic rat heterotopic heart transplantation was performed. Study 1: animals ( n = 5 each serotype) were killed at 21 days post-transplant to evaluate the efficiency of GFP transduction using RT-PCR and expression by fluorescence microscopy. Study 2: using rAAV-1, animals ( n = 5 each group) were killed at 7, 21 and 84 days to evaluate the durability of GFP expression. The maximum cardiac GFP expression at 21 days was observed in rAAV-1. GFP expression by rAAV-1 was detectable at 7 days, improved at 21 days, and was still evident at 84 days. This study demonstrates cardiac rAAV gene transduction with a cold perfusion preservation system of the donor heart. These data show that AAV-1 is superior to AAV-2 and AAV-5 for this purpose and that durable expression is achievable. [ABSTRACT FROM AUTHOR]

Background: Atrial fibrillation is the most common form of arrhythmia leading to hospital admission. Over 2.2 million Americans are affected by atrial fibrillation and approximately 160,000 new cases are identified annually. As the population continues to age, the number of patients will increase. AF is an incremental risk factor for death and stroke, and consumes billions of dollars in health care expenditures. Methods: Between August 2003 and October 2004, 50 drug-resistant, symptomatic atrial fibrillation patients underwent thoracoscopic or robotic-assisted off-pump epicardial microwave ablation with the FLEX 10 device (Guidant, Indianapolis, IN). There were 35 men (70.0%) and 15 women (30.0%), mean age 59.1 years ± 10.0 (range, 37-75 years). Mean duration of atrial fibrillation was 73.5 months ± 82.3 (range, 5-480 months). Thirty-three patients (66.0%) had intermittent atrial fibrillation and 17 (34.0%) continuous. Intermittent patients had pulmonary vein isolation whereas continuous patients had additional right and left atrial lesions performed. Forty-six patients (92.0%) had endoscopic stapling of the left atrial appendage. Results: There were no hospital deaths. Postoperative in-hospital complications were minimal with 2 patients (4.0%) experiencing diaphragmatic dysfunction. No patient required a permanent pacemaker implant. Mean postoperative length of stay was 3.7 ± 2.2 days. Cumulative follow-up was 335.8 patient months, mean 7.6 months (range, 2.0-15.9 months). There was 1 late death (2.0%). In 5 patients (10.0%) the MicroMaze operation and subsequent electrophysiology intervention failed and a Cox-Maze III operation was performed. Follow-up was 100% complete with 79.5% (35 of 44) patients in normal sinus rhythm. Conclusions: Totally endoscopic closed-chest microwave ablation for treatment of intermittent and continuous atrial fibrillation is technically feasible and presents minimal risk to the patient. Initial results are impressive and demonstrate an enhanced quality of life and freedom from atrial fibrillation in drug-resistant symptomatic patients. [Copyright &y& Elsevier]

The article outlines the study conducted on xenotransplantation using GT-KO pigs in the U.S. It reveals that one of the fundamental advantages of xenotransplantation is the donor organ, because it is derived from a pig which can be genetically modified to relieve the patient of immunosuppressive burden. The donor organs eliminated the need for systemic complement inhibition and reduced the immunosuppressive burden of the recipient.